Spots Global Cancer Trial Database for Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Official Title: Treatment of Ménétrier's Disease With EGF Receptor Blockade

Study ID: NCT00477880

Conditions

Gastric Cancer

Precancerous Condition

Interventions

Cetuximab

Study Description

Brief Summary: RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying how well cetuximab works in treating patients with Ménétrier disease at high risk of developing stomach cancer.

Detailed Description: OBJECTIVES: * Evaluate clinical and biochemical parameter response in patients with Ménétrier disease at high risk of developing gastric cancer treated with cetuximab. OUTLINE: This is a non-randomized study. Patients receive cetuximab IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients complete a quality of life questionnaire at baseline and during week 4. PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.